You are here

  • Home
  • Online First
  • Cognition in patients with myelin oligodendrocyte glycoprotein antibody-associated disease: a prospective, longitudinal, multicentre study of 113 patients (CogniMOG-Study)

Responses

Article menu
Cognition
Original research
Cognition in patients with myelin oligodendrocyte glycoprotein antibody-associated disease: a prospective, longitudinal, multicentre study of 113 patients (CogniMOG-Study)
Compose a Response to This Article
Compose Response

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on: 9 August 2024
    Evaluating Cognitive Impairments in MOGAD: A Critical Review of the CogniMOG-Study’s Findings
    • Ardavan Kafaei, General practitioner Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran

    To the Editor,
    I am writing to commend and engage with the recently published study, "Cognition in patients with myelin oligodendrocyte glycoprotein antibody-associated disease: a prospective, longitudinal, multicentre study of 113 patients (CogniMOG-Study)." (1). This pioneering work addresses a crucial yet underexplored aspect of MOGAD, namely its impact on cognitive function. The study represents a significant advancement in understanding cognitive impairments associated with this rare but impactful condition.
    Significance of Findings: The CogniMOG-Study provides a comprehensive assessment of cognitive function in MOGAD patients, revealing that while cognitive deficits are present, they are relatively limited compared to other neuroinflammatory conditions. The observed impairments in semantic fluency and processing speed are particularly noteworthy. These findings suggest that cognitive deficits in MOGAD primarily affect verbal and information processing domains, which are critical for daily functioning and quality of life.
    The study’s longitudinal design is a particular strength, allowing for the observation of cognitive changes over time. The absence of significant cognitive decline over the follow-up periods is an encouraging finding, suggesting stability in cognitive function among MOGAD patients. However, it also raises questions about the factors contributing to cognitive stability and the potential for practice effects, which merit fur...

    Show More
    Conflict of Interest:
    None declared.